| abstract |
An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid 5 (besylate) salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic anti-thrombotic effect whilst limiting drug-drug interactions with other concomitantly dosed drug/s, particularly those which are metabolised by CYP-450 enzymes. |